In the last three months, 11 analysts have published ratings on Sangamo Therapeutics SGMO, offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 9 | 1 | 1 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 3 | 0 | 1 | 0 | 0 |
2M Ago | 3 | 0 | 0 | 0 | 0 |
3M Ago | 2 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing the previous average price target of $7.73, the current average has increased by 4.66%.
Deciphering Analyst Ratings: An In-Depth Analysis
A clear picture of Sangamo Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Nicole Germino | Truist Securities | Lowers | Buy | $5.00 | $7.00 |
Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Maury Raycroft | Jefferies | Lowers | Buy | $3.00 | $7.00 |
Jim Birchenough | Wells Fargo | Lowers | Equal-Weight | $2.00 | $3.00 |
Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $10.00 | $10.00 |
Gena Wang | Barclays | Raises | Overweight | $9.00 | $3.00 |
Patrick Trucchio | HC Wainwright & Co. | Raises | Buy | $10.00 | $5.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sangamo Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sangamo Therapeutics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Sangamo Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.
For valuable insights into Sangamo Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Sangamo Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Sangamo Therapeutics's Background
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Understanding the Numbers: Sangamo Therapeutics's Finances
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Sangamo Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 425.77%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sangamo Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 18.99%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sangamo Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 29.88%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sangamo Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.19% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 0.71, Sangamo Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
How Are Analyst Ratings Determined?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.